Breast Cancer

Double Good News For AstraZeneca's Breast Cancer Drugs

In Less Than 2 Months, Federal Health Agency Has Granted $6.4M To Study Medical Marijuana In Cancer Patients

Cannabis Cares: MariMed Commits To Breast Cancer Initiative Via Its Betty's Eddies Brand

In Less Than 2 Months, Federal Health Agency Has Granted $6.4M To Study Medical Marijuana In Cancer Patients

Cannabis Cares: MariMed Commits To Breast Cancer Initiative Via Its Betty's Eddies Brand

Breast Cancer Awareness: How Can Marijuana Companies Help? Listen To An Expert On Benzinga's Cannabis Insider

New Data Shows Novartis' Kisqali Extends Survival In Postmenopausal Breast Cancer Setting

Breast Cancer Awareness: How Can Marijuana Companies Help? Listen To An Expert On Benzinga's Cannabis Insider

New Data Shows Novartis' Kisqali Extends Survival In Postmenopausal Breast Cancer Setting

Merck's Keytruda Regime Approved In Canada For Early Breast Cancer Setting

AIM ImmunoTech Shares Jump On Positive Data From Ampligen Study In Breast Cancer Setting

Breast Cancer Recent News

Celcuity Plans To Start Pivotal Gedatolisib Trial In Breast Cancer In 1H 2022

Why Sanofi Shares Are Trading Lower Today

Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer,

AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer

NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting

FDA Backs Immutep's Eftilagimod Registrational Trial In Metastatic Breast Cancer

Immutep Limited (NASDAQ: IMMP) has

Gilead Sciences' Trodelvy Study In Breast Cancer Meets Primary Endpoint

Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer.

AstraZeneca's Stock Gain After Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting

AstraZeneca plc (NASDAQ: AZN) said that

Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has

Merus Shares Updated Data From Zeno Triplet Combo Data In Breast Cancer Settings

Merus NV (NASDAQ: MRUS) has

Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial

Infinity Pharmaceuticals Inc (NASDAQ: INFI)

Arvinas, Pfizer's ARV-471 Shows Clinical Benefit Rate Of 40% In Pretreated Breast Cancer Patients

Context Therapeutics Shares Surge On Encouraging Data From Onapristone In Early Breast Cancer

Context Therapeutics Inc (NASDAQ: CNTX) posted

Ambrx Biopharma Shares Jump After Safety, Efficacy Data From Breast Cancer Trial

Ambrx Biopharma Inc's (NYSE: AMAM) partner in China, NovoCodex Pharmaceuticals Ltd, presented

Seagen Tukysa Maintains Survival Benefit, Delays Cancer Progression In The Brain In Breast Cancer Patients

Seagen Inc (NASDAQ: SGEN) has

Novartis' New Kisqali Data Shows Consistent Overall Survival Benefit Across Metastatic Breast Cancer Settings

Radius Health Reveals Detailed Elacestrant Data From Late-Stage Breast Cancer Trial

The Menarini Group and Radius Health Inc (NASDAQ: RDUS) have

After Denying Data Leak, Olema Shares First Data For Lead Program In Breast Cancer Patients

Olema Pharmaceuticals Inc (NASDAQ: OLMA) had been preparing to present the first clinical data from its lead program in development for metastatic breast cancer at a

AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting

The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: <

Merck's Keytruda Conditionally Approved In Canada For Triple-Negative Breast Cancer

Gilead's Trodelvy Approved In Europe For Aggressive Form Of Breast Cancer

The European Commission has approved Gilead Sciences Inc's (NASDAQ:

Athenex To Present Subgroup Analysis Of Oral Paclitaxel-Encequidar Combo Data From Breast Cancer Trial

Athenex Inc's (NASDAQ: ATNX) abstract for subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar (Oral Paclitaxel) for metastatic breast cancer has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium.

Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients

Jaguar Health Inc (NASDAQ: JAGX)

Immutep's Lead Candidate Data In Breast Cancer Trial Fails To Lift The Stock